Evidence map›Paper›PMID 25785833›Full record

ArticlePloS one2015

Knockdown of CDK2AP1 in primary human fibroblasts induces p53 dependent senescence.

Khaled N Alsayegh, Venkat S Gadepalli, Shilpa Iyer, Raj R Rao

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.7field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 11 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Epigenetic regulation in cell senescence.Journal of molecular medicine (Berlin, Germany) · 2017
    Review
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 2 countries.

Khaled N AlsayeghDepartment of Human and Molecular Genetics, Virginia Commonwealth University, Richmond, United States of America; King Abdullah International Medical Research Center, King Saud bin Abdulaziz University for Health Sciences, Jeddah, Saudi Arabia.
Venkat S GadepalliIntegrated Life Sciences Program, Virginia Commonwealth University, Richmond, Virginia, United States of America.
Shilpa IyerCenter for the Study of Biological Complexity, Life Sciences Program, Virginia Commonwealth University, Richmond, Virginia, United States of America; Department of Chemical and Life Sciences Engineering, Virginia Commonwealth University, Richmond, Virginia, United States of America.
Raj R RaoDepartment of Human and Molecular Genetics, Virginia Commonwealth University, Richmond, United States of America; Integrated Life Sciences Program, Virginia Commonwealth University, Richmond, Virginia, United States of America; Center for the Study of Biological Complexity, Life Sciences Program, Virginia Commonwealth University, Richmond, Virginia, United States of America; Department of Chemical and Life Sciences Engineering, Virginia Commonwealth University, Richmond, Virginia, United States of America; Massey Cancer Center, Virginia Commonwealth University, Richmond, Virginia, United States of America.
Virginia Commonwealth University · USKing Saud bin Abdulaziz University for Health Sciences · SA

Funding

Center for Clinical and Translational ResearchUL1TR000058 · NCATS · VIRGINIA COMMONWEALTH UNIVERSITY · PI MOELLER, FREDERICK GERARD · 2012 to 2015
$12.5M
mtDNA heteroplasmy in development and differentiation: an in-vitro approachR15NS080157 · NINDS · VIRGINIA COMMONWEALTH UNIVERSITY · PI IYER, SHILPA · 2013 to 2013
$352k
NCATS NIH HHS UL1 TR000058NCATS NIH HHS UL1TR000058NINDS NIH HHS R15 NS080157
6 · The paper itself

Abstract

Cyclin Dependent Kinase-2 Associated Protein-1 (CDK2AP1) is known to be a tumor suppressor that plays a role in cell cycle regulation by sequestering monomeric CDK2, and targeting it for proteolysis. A reduction of CDK2AP1 expression is considered to be a negative prognostic indicator in patients with oral squamous cell carcinoma and also associated with increased invasion in human gastric cancer tissue. CDK2AP1 overexpression was shown to inhibit growth, reduce invasion and increase apoptosis in prostate cancer cell lines. In this study, we investigated the effect of CDK2AP1 downregulation in primary human dermal fibroblasts. Using a short-hairpin RNA to reduce its expression, we found that knockdown of CDK2AP1 in primary human fibroblasts resulted in reduced proliferation and in the induction of senescence associated beta-galactosidase activity. CDK2AP1 knockdown also resulted in a significant reduction in the percentage of cells in the S phase and an accumulation of cells in the G1 phase of the cell cycle. Immunocytochemical analysis also revealed that the CDK2AP1 knockdown significantly increased the percentage of cells that exhibited γ-H2AX foci, which could indicate presence of DNA damage. CDK2AP1 knockdown also resulted in increased mRNA levels of p53, p21, BAX and PUMA and p53 protein levels. In primary human fibroblasts in which p53 and CDK2AP1 were simultaneously downregulated, there was: (a) no increase in senescence associated beta-galactosidase activity, (b) decrease in the number of cells in the G1-phase and increase in number of cells in the S-phase of the cell cycle, and (c) decrease in the mRNA levels of p21, BAX and PUMA when compared with CDK2AP1 knockdown only fibroblasts. Taken together, this suggests that the observed phenotype is p53 dependent. We also observed a prominent increase in the levels of ARF protein in the CDK2AP1 knockdown cells, which suggests a possible role of ARF in p53 stabilization following CDK2AP1 knockdown. Altogether, our results show that knockdown of CDK2AP1 in primary human fibroblasts reduced proliferation and induced premature senescence, with the observed phenotype being p53 dependent.

Indexed as

Gene Knockdown TechniquesApoptosis Regulatory Proteinsbcl-2-Associated X ProteinCell CycleCell ProliferationCellular SenescenceCyclin-Dependent Kinase Inhibitor p21DNA DamageFibroblastsHumansProto-Oncogene ProteinsRNA, Small InterferingTumor Suppressor Protein p14ARFTumor Suppressor Protein p53Tumor Suppressor ProteinsApoptosis Regulatory ProteinsBBC3 protein, humanbcl-2-Associated X ProteinCDK2AP1 protein, humanCyclin-Dependent Kinase Inhibitor p21Proto-Oncogene ProteinsRNA, Small InterferingTumor Suppressor Protein p14ARFTumor Suppressor Protein p53Tumor Suppressor Proteins

Identifiers

PMID25785833
PMCPMC4365013
OpenAlexW2038209761

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.